Please login to the form below

Not currently logged in

plaque psoriasis

This page shows the latest plaque psoriasis news and features for those working in and with pharma, biotech and healthcare.

GSK sells eczema and psoriasis drug to Dermavant for £250m

GSK sells eczema and psoriasis drug to Dermavant for £250m

GSK sells eczema and psoriasis drug to Dermavant for £250m. The British group is selling off assets outside core therapy areas to boost its R&D. ... In phase II trials the drug had a dose-dependent impact on plaque psoriasis lesions, and it is ready to

Latest news

More from news
Approximately 6 fully matching, plus 81 partially matching documents found.

Latest Intelligence

  • Pharma deals continue to slide Pharma deals continue to slide

    Pre-registration (US) topical high potency steroid for moderate to severe plaque psoriasis.

  • 'Nothing about us without us' 'Nothing about us without us'

    Similarly, Novartis - which issued a patient declaration committing, among other things, to inviting patient input early on in their clinical trial process - recently invited people living with plaque psoriasis to attend

  • Deal Watch March 2017 Deal Watch March 2017

    Merck KGaA has partnered its product M1095 (ALX-0761), for plaque psoriasis, to Avillion.

  • Deal Watch July 2016 Deal Watch July 2016

    The product completed Phase 3 studies in moderate to severe plaque psoriasis in May 2016 and announced that the primary endpoints had been met. ... Acquisition. 78. Sun Pharma/ Almirall. Tildrakizumab (IL-23p19 inhibitor) - psoriasis. Licence.

  • Deal Watch March 2016 Deal Watch March 2016

    Two deals involved products at a later stage of development: Dr Reddy's licence for Xenoport's phase II product XP23829 for plaque psoriasis, and Ipsen's licence for Exelixis's ... Collaboration – development. $595. Xenoport/ Dr Reddy's. XP-23829 for

More from intelligence
Approximately 0 fully matching, plus 5 partially matching documents found.

Featured jobs

Subscribe to our email news alerts


Add my company
GEM Marketing Ltd

GEM, a small but perfectly formed integrated marketing agency servicing the pharmaceutical industry....

Latest intelligence

Developing advocacy in the pharmaceutical industry.
The importance of advocacy programmes...
GDPR and events. What does the pharma industry need to know?
Many people in the pharma industry still aren’t following the rules set out by the GDPR when it comes to running events and attending tradeshows. But with eye-watering fines for...
Digital trends in B2B sales - how far behind is Pharma?
The modern approach to B2B sales is data-driven, and enabled by digital tools....